Table 1 General characteristics of the study population.
From: A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval
Variables | Rosuvastatin (n = 228) | Atorvastatin (n = 238) | p-Value |
|---|---|---|---|
Age (years) | 63.71 ± 10.97 | 64.96 ± 11.32 | 0.229 |
Male | 129 (56.6%) | 145 (60.9%) | 0.341 |
Female | 99 (43.4%) | 93 (39.1%) | |
Height (cm) | 163.11 ± 8.35 | 163.26 ± 8.00 | 0.847 |
Weight (kg) | 66.61 ± 11.84 | 66.45 ± 11.53 | 0.884 |
Smoking | 76 (33.3%) | 80 (33.6%) | 0.949 |
Drinking | 54 (23.7%) | 42 (17.6%) | 0.107 |
Hypertension | 128 (56.1%) | 140 (58.8%) | 0.558 |
Diabetes | 47 (20.6%) | 48 (20.2%) | 0.905 |
Atrial fibrillation | 17 (7.5%) | 13 (5.5%) | 0.381 |
Chronic heart failure | 18 (7.9%) | 22 (9.2%) | 0.603 |
Biochemical indicators | |||
Creatinine (µmoI/L) | 69.40 ± 18.25 | 74.90 ± 42.79 | 0.074 |
AST (U/L) | 24.49 ± 8.24 | 24.63 ± 11.17 | 0.879 |
ALT (U/L) | 22.84 ± 17.15 | 21.87 ± 14.80 | 0.512 |
Serum potassium (mmoI/L) | 3.89 ± 0.32 | 3.94 ± 0.35 | 0.090 |
Serum calcium (mmoI/L) | 2.26 ± 0.10 | 2.27 ± 0.10 | 0.151 |
Serum magnesium (mmoI/L) | 0.86 ± 0.07 | 0.85 ± 0.06 | 0.600 |
Serum sodium (mmoI/L) | 140.25 ± 1.86 | 140.27 ± 1.90 | 0.914 |
Total cholesterol (mmol/L) | 4.78 ± 1.06 | 4.88 ± 1.18 | 0.351 |
LDL-C (mmol/L) | 2.73 ± 0.64 | 2.81 ± 0.73 | 0.245 |
HDL-C (mmol/L) | 1.20 ± 0.26 | 1.19 ± 0.26 | 0.816 |
Triglycerides (mmol/L) | 1.58 ± 1.13 | 1.62 ± 1.34 | 0.779 |
Lipoprotein (a) mg/dL | 20.11 ± 22.38 | 17.30 ± 17.50 | 0.130 |
Inpatient medication | |||
Aspirin | 186 (81.6%) | 200 (84.0%) | 0.482 |
Clopidogrel | 182 (79.8%) | 199 (83.6%) | 0.246 |
Pantoprazole | 185 (81.1%) | 203 (85.3%) | 0.230 |
Isosorbide mononitrate | 35 (15.4%) | 36 (15.1%) | 0.946 |
Beta-blocker | 25 (11.0%) | 42 (17.6%) | 0.040 |
ACEI/ARB/ARNI | 68 (29.8%) | 81 (34.0%) | 0.330 |
Calcium channel blocker | 58 (25.4%) | 57 (23.9%) | 0.709 |
Loop diuretic | 18 (7.89%) | 12 (5.04%) | 0.210 |
Insulin | 1 (0.4%) | 2 (0.8%) | 0.588 |
Metformin | 15 (6.6%) | 19 (8.0%) | 0.552 |
SGLT-2i | 9 (3.9%) | 17 (7.1%) | 0.133 |
α-glucosidase inhibitor | 8 (3.5%) | 5 (2.1%) | 0.356 |
Sulphonylurea | 17 (7.5%) | 9 (3.9%) | 0.084 |
Thiazolidinedione | 3 (1.3%) | 2 (0.8%) | 0.618 |
Anticoagulant | 17 (7.5%) | 15 (6.3%) | 0.623 |
Estazolam | 2 (0.9%) | 3 (1.3%) | 0.688 |
Ultrasonic cardiogram | |||
LVEF (%) | 64.36 ± 7.15 | 63.80 ± 7.55 | 0.411 |
LVDd (mm) | 47.56 ± 4.68 | 47.65 ± 5.28 | 0.854 |
IVST (mm) | 10.88 ± 1.56 | 10.83 ± 1.62 | 0.718 |
LVPW (mm) | 9.86 ± 1.32 | 9.93 ± 1.28 | 0.592 |
Baseline ECG | |||
Heart rate (bpm) | 71.83 ± 12.20 | 73.77 ± 12.51 | 0.091 |
QT interval (ms) | 391.89 ± 38.51 | 392.43 ± 34.83 | 0.874 |
QTc interval (ms) | 425.85 ± 26.54 | 430.34 ± 29.32 | 0.084 |
Followed - up ECG | |||
Heart rate (bpm) | 68.14 ± 10.99 | 69.04 ± 10.85 | 0.371 |
QT interval (ms) | 408.96 ± 34.21 | 404.05 ± 35.93 | 0.131 |
QTc interval (ms) | 432.42 ± 28.46 | 429.51 ± 29.04 | 0.276 |
